IRIS
BOTTA, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.948
EU - Europa 22.106
AS - Asia 3.671
SA - Sud America 54
OC - Oceania 45
AF - Africa 31
Continente sconosciuto - Info sul continente non disponibili 26
Totale 56.881
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.858
GB - Regno Unito 7.281
IE - Irlanda 4.253
CN - Cina 3.156
UA - Ucraina 2.694
SE - Svezia 2.101
IT - Italia 1.577
FR - Francia 1.525
DE - Germania 1.461
FI - Finlandia 661
TR - Turchia 154
VN - Vietnam 140
BE - Belgio 122
ES - Italia 119
CA - Canada 76
RO - Romania 67
IN - India 53
RU - Federazione Russa 50
AU - Australia 41
NL - Olanda 41
HK - Hong Kong 29
JP - Giappone 27
EU - Europa 25
IR - Iran 25
GR - Grecia 23
BR - Brasile 22
PL - Polonia 20
SG - Singapore 17
CL - Cile 15
CZ - Repubblica Ceca 14
EG - Egitto 14
BG - Bulgaria 10
CH - Svizzera 10
EE - Estonia 10
KR - Corea 10
HU - Ungheria 9
TH - Thailandia 7
ZA - Sudafrica 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
DK - Danimarca 6
LV - Lettonia 6
HR - Croazia 5
NO - Norvegia 5
PA - Panama 5
PT - Portogallo 5
SK - Slovacchia (Repubblica Slovacca) 5
AL - Albania 4
AZ - Azerbaigian 4
BD - Bangladesh 4
BO - Bolivia 4
CO - Colombia 4
ID - Indonesia 4
IL - Israele 4
IM - Isola di Man 4
LK - Sri Lanka 4
MA - Marocco 4
NZ - Nuova Zelanda 4
EC - Ecuador 3
JO - Giordania 3
KZ - Kazakistan 3
MK - Macedonia 3
RS - Serbia 3
SA - Arabia Saudita 3
TN - Tunisia 3
AM - Armenia 2
AR - Argentina 2
DO - Repubblica Dominicana 2
IQ - Iraq 2
LU - Lussemburgo 2
MD - Moldavia 2
MX - Messico 2
PE - Perù 2
PH - Filippine 2
PR - Porto Rico 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BT - Bhutan 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GH - Ghana 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
MS - Montserrat 1
MY - Malesia 1
PK - Pakistan 1
SC - Seychelles 1
SI - Slovenia 1
TJ - Tagikistan 1
TW - Taiwan 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 56.881
Salva come PNG Salva come JPEG
Città #
Southend 6.751
Fairfield 4.514
Dublin 4.217
Menlo Park 3.597
Chandler 2.526
Jacksonville 2.252
Ashburn 2.156
Woodbridge 2.105
Wilmington 1.755
Seattle 1.623
Houston 1.601
Cambridge 1.563
Ann Arbor 1.314
Nanjing 820
Princeton 804
Beijing 724
Siena 673
New York 359
Boardman 324
Nanchang 306
San Diego 265
Helsinki 230
San Mateo 201
Shenyang 175
Düsseldorf 153
Dong Ket 138
Shanghai 130
Hebei 129
Fremont 121
Izmir 121
Venezia 121
Tianjin 119
Brussels 114
Changsha 108
Dearborn 108
Kunming 103
Milan 89
Málaga 89
London 88
Jiaxing 87
Norwalk 75
Lancaster 72
Redwood City 69
Jinan 68
San Francisco 60
Hangzhou 54
Ningbo 49
Toronto 49
Zhengzhou 48
Mestre 43
Timisoara 43
Florence 39
Rome 36
Philadelphia 33
Guangzhou 31
Taizhou 29
Changchun 28
Washington 25
Kilburn 24
Lanzhou 24
Phoenix 24
Los Angeles 19
Amsterdam 17
Frankfurt am Main 17
Leawood 17
Edinburgh 16
Hefei 16
Melbourne 16
Hong Kong 15
Tappahannock 15
Hounslow 14
Paris 14
Salamanca 14
Cairo 13
Saint Petersburg 13
Canberra 12
Grünheide 12
Sydney 12
Chicago 11
Fuzhou 11
Lappeenranta 11
Pune 11
São Paulo 11
Zanjan 11
Bonndorf 10
Sofia 10
Tallinn 10
Tokyo 10
Besançon 9
Chiswick 9
Gdynia 9
Haikou 9
Indiana 9
Nashville 9
Prague 9
Auburn Hills 8
Cagliari 8
Falls Church 8
Islington 8
New Bedfont 8
Totale 44.057
Salva come PNG Salva come JPEG
Nome #
1,5-Diarylpyrrole-3-acetic Acids and Esters as Novel Classes of Potent and Highly Selective Cyclooxygenase-2 Inhibitors 325
1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: design, synthesis, and microbiological evaluation 293
1,5-Diphenylpyrrole Derivatives as Antimycobacterial Agents. Probing the Influence on Antimycobacterial Activity of Lipophilic Substituents at the Phenyl Rings 279
1-[(3-Aryloxy-3-aryl)propyl]-2H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies 271
Prodrugs of pyrazolo[3,4-d]pyrimidines: from library synthesis to evaluation as potential anticancer agents in an orthotopic glioblastoma model 259
4-Substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof 243
Identification, synthesis and biological activity of alkyl-guanidine oligomers as potent antibacterial agents 220
Pyrrole compounds as inhibitors of mycobacteria, synthesis thereof ans intermediates thereto 219
Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: Nanosystem approaches for drug delivery 218
Structure, function, involvement in diseases and targeting of 14-3-3 proteins: An Update 208
Linear guanidine derivatives, methods of preparation and uses thereof 206
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 206
Chemically stable inhibitors of 14-3-3 protein–protein interactions derived from BV02 203
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor 203
New macrocyclic amidinourea derivatives, methods of preparation and uses thereof as chitinase inhibitors 201
Pyrazolo[3,4-d]pyrimidines-loaded human serum albumin (HSA) nanoparticles: preparation, characterization and cytotoxicity evaluation against neuroblastoma cell line 198
Derives substitues en 4 de pyrazolo[3,4-d]pyrimidine et pyrrolo[2,3-d]pyrimidine et utilisations associees 196
Biological Characterization and in Vivo Assessment of the Activity of a New Synthetic Macrocyclic Antifungal Compound 194
Potent and selective carboxylic acid inhibitors of tumor-associated carbonic anhydrases IX and XII 189
Functionalized Graphene Derivatives: Antibacterial Properties and Cytotoxicity 187
Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma. 186
4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling 185
Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands 185
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors 185
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 184
Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3σ protein-protein interactions 183
New 4-substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof 182
CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction. 182
2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors 181
SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment. 180
‘LC/ESI/MS method for the quantitative detection of guazatine residues in cereales’ 177
Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors 175
Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization 174
Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria 171
DDX3X Helicase Inhibitors as a New Strategy to Fight the West Nile Virus Infection 170
Differentially activated Src kinase in chemo-naive human primary osteosarcoma cells and effects of a Src kinase inhibitor 169
Arylation of 2-Furyl 4-Fluorophenyl Ketone: an extension of Heck Chemistry towards Novel Integrase Inhibitors 167
Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication. 166
Design, synthesis, biological activity and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study 166
Lc/Esi/Ms/Ms determination of postharvest fungicide residues in citrus juices 166
Discovery of in vitro antitubercular agents through in silico ligand-based approaches 166
Antihypertensive, cardio-and neuroprotective effects of Tenebrio molitor (Coleoptera: Tenebrionidae) defatted larvae in spontaneously hypertensive rats 166
Synthesis of an original oxygenated taxuspine X analogue: a versatile non-natural natural product with remarkable P-gp modulating activity 165
N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl 165
New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation 164
Tautomers of a Fluorescent G Surrogate and Their Distinct Photophysics Provide Additional Information Channels 162
Pyrazolo[3,4-d]pyrimidines Endowed with Antiproliferative Activity on Ductal Infiltrating Carcinoma Cells 162
Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3s case 161
2-Aminothiazolones as anti-hiv agents that act as gp120-cd4 inhibitors 161
Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family 161
Antifungal agents. 10. New derivatives of 1-[(Aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-Candida activity and Quantitative Structure-Analysis Relationship studies 161
Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents 160
Pirazolo[3,4-d]pirimidine come nuovi agenti antiproliferativi. Sviluppo di un modello 3D QSAR a bassa dipendenza conformazionale 158
The fight against the influenza A virus H1N1: synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors. 158
4-Substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof 157
Cardiovascular Characterization of Pyrrolo[2,1-d][1,5]benzothiazepine Derivatives Binding Selectively to the Peripheral-Type Benzodiazepine Receptor (PBR):  From Dual PBR Affinity and Calcium Antagonist Activity to Novel and Selective Calcium Entry Blockers 157
Dihydro-alkylthio-benzyl-oxopyrimidines as Inhibitors of Reverse Transcriptase: Synthesis and Rationalization of the Biological Data on Both Wild-Type Enzyme and Relevant Clinical Mutants 156
Plasmin-Binding Tripeptide-Decorated Liposomes Loading Pyrazolo[3,4- d]pyrimidines for Targeting Hepatocellular Carcinoma 156
Docking, 3D-QSAR studies and in silicoADME prediction on c-Src tyrosine kinase inhibitors 155
Dietary fatty acids influence the growth and fatty acid composition of the yellow mealworm Tenebrio molitor (Coleoptera: Tenebrionidae) 155
Microwave-assisted organocatalytic multicomponent Knoevenagel/Hetero Diels Alder reaction for the synthesis of 2,3-dihydropyran[2,3-c]pyrazoles 154
From Taxuspine X to structurally simplified Taxanes with remarkable P-Glycoprotein inhibitory activity 154
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212 154
3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors 154
Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation 154
Discovery of 14-3-3 Protein-Protein Interaction Inhibitors that Sensitize Multidrug-Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693 154
Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data 153
null 153
Enlarging the NSAIDs Family: Ether, Ester and Acid Derivatives of the 1,5-Diarrylpyrrole Scaffold as novel anti-inflammatory and analgesic agents 152
Simplified Analogues of Immucillin-G Retain Potent Human Purine Nucleoside Phosphorylase Inhibitory Activity 152
158. Preparation of analogues of 1-{[1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]methyl}-4-methylpiperazine as antitubercular agents 152
Proteomics and phosphoproteomics provide insights into the mechanism of action of a novel pyrazolo[3,4-d]pyrimidine Src inhibitor in human osteosarcoma 152
Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant 152
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 152
Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 151
Towards novel S-DABOC inhibitors: Synthesis, biological investigation, and molecular modeling studies. 150
The anti-HIV activity of ADS-J1 targets the HIV-1 gp120 150
Pyrrolo[2,1-c][1,4]benzothiazines: Synthesis, Structure-Activity Relationships, Molecular Modeling Studies, and Cardiovascular Activity 150
3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors 149
4­-Amino­substituted pyrazolo[3,4­d]pyrimidines: synthesis and biological properties 149
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment 149
Computational studies of competitive inhibitors of nitric oxide synthase (NOS) enzymes: towards the development of powerful and isoform-selective inhibitors. 148
Diltiazem-like calcium entry blockers: a hypothesis of the receptor-binding site based on a comparative molecular field analysis model 147
Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors 146
Pyrrole compounds as inibitors of mycobacteria, synthesis thereof and intermediates thereto 145
Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors 145
Crystal Structure of HIV-1 Reverse Transcriptase Bound to a Non-Nucleoside Inhibitor with a Novel Mechanism of Action 145
Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells. 145
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 145
Exploration of novel thiobarbituric acid- rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors 144
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 1. Synthesis and Structure-Activity Relationship of a Class of Human Immunodeficiency Virus type 1 Integrase Inhibitors. 144
Design and synthesis of a novel inhibitor of T. Viride chitinase through an in silico target fishing protocol 144
null 143
α1-Adrenoceptor antagonists. 5. Pyridazinone-arylpiperazines. Probing the influence on affinity and selectivity of both ortho-Alkoxy groups at the arylpiperazine moiety and cyclic substituents at the pyridazinone nucleus 143
Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction 143
Synthesis and Interaction with Copper(II) Cations of Cyano- and Aminoresorcin[4]arenes 142
Synthesis of reactive cytidine derivatives as building blocks for cross-linking oligonucleotides 142
Structure Prediction and Validation of the ERK8 Kinase Domain 142
Multitarget hedgehog pathway inhibitors and uses thereof 142
Probing the role of Arg97 in Heat shock protein 90 N-terminal domain from the parasite Leishmania braziliensis through site-directed mutagenesis on the human counterpart 142
Totale 17.185
Salva come PNG Salva come JPEG
Categoria #
all - tutte 161.662
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 161.662
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193.403 0 0 0 0 0 0 0 0 0 0 1.732 1.671
2019/202012.326 1.602 477 804 2.106 803 916 997 1.574 1.018 1.003 272 754
2020/20218.622 474 906 173 906 488 1.115 373 1.296 993 631 647 620
2021/20225.949 455 961 297 298 239 190 331 201 336 663 642 1.336
2022/20238.971 578 734 1.197 1.330 904 1.765 191 766 897 160 300 149
2023/20245.567 262 127 410 285 189 1.749 2.181 211 22 125 6 0
Totale 57.331